The stabbing occurred inside a Blue Line train car at the Clark and Lake stop downtown just before 2:30 a.m. Filming nude ...

As the United States approaches its 250th anniversary, Rosie Rios, Chair of America250, offered a first look at the super centennial programs celebrating the American spirit of innovation and ...

Domestic companies should maintain clear ownership and control records and stay ready for potential changes; foreign ...

The feds delivered the CTA a blow at the end of last year when the Federal Transit Administration threatened to cut funding if the agency didn't improve safety. The big picture: Safety is just one of ...

Sarepta is also pursuing preclinical programs for Spinocerebellar ataxia type 1 (SCA1) and Spinocerebellar ataxia type 3 (SCA3) and has an exclusive collaboration with Arrowhead Pharmaceuticals to ...

With a record-number of CES Innovation Awards (R) 2026 submissions, additional honorees were recognized this week. Attendees can explore select winning products in person at the CES Innovation Awards ...

CES® 2026 officially opens its doors today, welcoming visionaries, industry and government leaders, investors, and media to the global gathering place for technology. Spanning more than 2.6M net ...

Call to Action Foundation is pleased to announce the opening of its 2026 CTA Scholarship Program, continuing its commitment to supporting students in pursuit of higher ...

The CTA No Objection Letter from Health Canada allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers. The ALSTARS Trial is a phase 2, placebo-controlled study that ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) The CTA No ...

Ensoma recently announced the dosing of the first US patient in the multinational Phase I/II trial of EN-374. Credit: Volha_R / Shutterstock.com. The UK Medicines and Healthcare Products Regulatory ...